Loading stock data…
Becton (BDX)
$155.19-0.73 (-0.47%)
Market ClosedLast close Jun 29
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Becton, Dickinson and Company in the Healthcare sector is trading at $155.19 with a market capitalization of $40.1B. Wall Street consensus targets $177.75 (12 analysts), implying a +14.5% move over the next 12 months. The stock is currently 17% below its 52-week high of $187.35, remaining 2.0% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +14.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $4.71B↓ | $5.25B↓ | $5.89B↑ | $5.51B↑ | $4.48B |
| Gross Profit | $2.15B↓ | $2.41B↓ | $2.80B↑ | $2.63B↑ | $1.86B |
| Operating Income | $626.00M↓ | $662.00M↓ | $826.00M↓ | $979.00M↑ | $477.00M |
| Net Income | -$311.00M↓ | $382.00M↓ | $493.00M↓ | $574.00M↑ | $308.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$40.12B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Strong income play. Yield provides a meaningful total return floor.
2.27%
ROE
Average efficiency. Growth may require heavy reinvestment.
4.72%
Volume
Today's trading volume
2.36M
Recent News
How Are Emerging Markets Supporting Abbott's EPD Momentum?
ABT's Emerging Markets drive EPD growth, with strong branded generics demand, biosimilar expansion and new approvals boosting momentum.
Becton Dickinson (BDX) Issues Voluntary Recall for Select Skin Preparation Products
Becton, Dickinson and Company (NYSE:BDX) is one of the 10 Cheap Jim Cramer Stocks to Invest In Right Now. On June 6, 2026, Becton, Dickinson and Company (NYSE:BDX) issued a nationwide voluntary recall for specific lots of its ChloraPrep™ Clear 1 mL and FREPP™ Clear 1.5 mL skin preparation applicators due to potential fungal contamination […]
How to Approach Abbott Stock Following Its Sharp YTD Decline?
ABT falls 29.4% YTD as respiratory testing weakness, China uncertainty and acquisition dilution pressure results and outlook.
3 Excellent Dividend Stocks to Buy on the Dip
Don't wait too long to get in on these outstanding dividend payers.
Will CONMED’s New CFO Shift CNMD’s Financial Playbook Or Deepen Its Existing Strategy?
On June 17, 2026, CONMED Corporation announced that John E. Gallagher will become Executive Vice President, Chief Financial Officer, and principal financial and accounting officer from July 15, 2026, succeeding Todd Garner, who will remain in an advisory role until November 2, 2026. Gallagher’s nearly three decades of finance leadership across healthcare and industrial companies, including senior roles at Certara, Cue Health, and Becton Dickinson, signals a refreshed approach to CONMED’s...